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Summary
Background Increasing insecticide costs and constrained malaria budgets could make universal vector control 
strategies, such as indoor residual spraying (IRS), unsustainable in low-transmission settings. We investigated the 
effectiveness and cost-effectiveness of a reactive, targeted IRS strategy.
Methods This cluster-randomised, open-label, non-inferiority trial compared reactive, targeted IRS with standard IRS 
practice in northeastern South Africa over two malaria seasons (2015–17). In standard IRS clusters, programme 
managers conducted annual mass spray campaigns prioritising areas using historical data, expert opinion, and other 
factors. In targeted IRS clusters, only houses of index cases (identified through passive surveillance) and their 
immediate neighbours were sprayed. The non-inferiority margin was 1 case per 1000 person-years. Health service 
costs of real-world implementation were modelled from primary and secondary data. Incremental costs per disability-
adjusted life-year (DALY) were estimated and deterministic and probabilistic sensitivity analyses conducted. This 
study is registered with ClinicalTrials.gov, NCT02556242.
Findings Malaria incidence was 0·95 per 1000 person-years (95% CI 0·58 to 1·32) in the standard IRS group and 
1·05 per 1000 person-years (0·72 to 1·38) in the targeted IRS group, corresponding to a rate difference of 0·10 per 
1000 person-years (–0·38 to 0·59), demonstrating non-inferiority for targeted IRS (p<0·0001). Per additional DALY 
incurred, targeted IRS saved US$7845 (2902 to 64 907), giving a 94–98% probability that switching to targeted IRS 
would be cost-effective relative to plausible cost-effectiveness thresholds for South Africa ($2637 to $3557 per DALY 
averted). Depending on the threshold used, targeted IRS would remain cost-effective at incidences of less than 
2·0–2·7 per 1000 person-years. Findings were robust to plausible variation in other parameters.
Interpretation Targeted IRS was non-inferior, safe, less costly, and cost-effective compared with standard IRS in this 
very-low-transmission setting. Saved resources could be reallocated to other malaria control and elimination activities.
Funding Joint Global Health Trials.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction 
The mass scale-up of malaria control interventions in 
endemic countries has driven major reductions in malaria 
morbidity and mortality over the past two decades. 
From 2000 to 2019, malaria case incidence in the WHO 
African Region declined by 38%, from 363 to 225 per 
1000 population at risk, and the malaria mortality rate 
decreased by 67%, from 121 to 40 deaths per 100 000 popula-
tion at risk.1 Vector control had a pivotal role in this success 
and was responsible for an estimated 78% of malaria cases 
averted between 2000 and 2015.2
Over the past few years, however, progress has stalled 
and, in some areas, reversed.1 Several factors probably 
contributed towards this trend. Although funding 
for malaria control and elimination greatly increased 
between 2000 and 2010, it has plateaued since.1 Global 
malaria funding fell from $3·2 billion in 2017 to 
$3·0 billion in 2019, well below the estimated $5·6 billion 
required annually to remain on track towards the WHO 
global malaria strategy targets.1 Widespread and 
increasing insecticide resistance has compromised the 
effectiveness of low-cost, pyrethroid-based vector 
control.3–5 The substantially higher costs of vector control 
with new or repurposed insecticides to address resis-
tance6–8 add considerably to budgetary challenges.
More efficient strategies are therefore required to reduce 
malaria transmission. Where transmission is already very 
low, universal application of mass interventions might 
be unwarranted and unsustainable. Modelling studies 
suggest that targeting interventions to areas where there 
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is evidence of recent malaria transmission is less costly 
and might be similarly effective compared with blanket 
strategies.9–11 Evidence from randomised trials shows 
that adding reactive, targeted interventions to existing 
population-wide routine interventions can be effective in 
further reducing malaria in low-transmission settings.12–14 
However, no study has investigated whether widespread 
deployment of malaria interventions, such as indoor 
residual spraying (IRS), can be safely replaced by reactive, 
targeted interventions.
IRS is recommended as a primary malaria vector 
control method by WHO, has been adopted as policy by 
national malaria control programmes in 42 African 
countries,1 and has contributed substantially to reducing 
malaria in many countries, including South Africa.15–18 
IRS consists of the application of insecticide to the 
interior walls of houses at least once per year, usually by 
seasonal spray personnel. Training, organising, and 
supervising sprayers can be logistically challenging and 
result in poor quality insecticide application and 
inadequate spray coverage.19 More judicious deployment 
of IRS could therefore achieve comparable effectiveness 
at lower cost in low-transmission settings. We aimed to 
assess the non-inferiority, cost, and cost-effectiveness of 
reactive, targeted IRS compared with standard IRS.
Methods 
Study design and clusters
We did a cluster-randomised, open-label, non-inferiority 
trial in a low-transmission area of northeastern 
South Africa. Malaria transmission is low in South Africa 
and confined to border districts of the three northeastern 
provinces of Mpumalanga, Limpopo, and KwaZulu-Natal. 
From 2010 to 2014, an annual mean of 8781 cases was 
recorded nationally,1 of which a high proportion were 
imported.20 The primary vector is Anopheles arabiensis,21 
and Plasmodium falciparum accounts for nearly all 
cases.1 IRS has been the primary malaria control 
strategy in South Africa since 1945.22 At the time of our 
study, pyrethroid insecticides were used for painted 
surfaces and dichloro-diphenyl-trichloroethane (DDT) 
for the relatively small proportion of surfaces that are 
unpainted.21
Malaria is notifiable by legal statute in South Africa. In 
malaria risk areas, clinical guidelines require all febrile 
patients presenting at (public and private) health facilities 
be tested for malaria by rapid diagnostic tests (First 
Response Malaria Ag P falciparum HRP2 Test; Premier 
Medical Corporation; Mumbai, India) or microscopy. 
Uncomplicated malaria cases are treated with artemether-
lumefantrine.23 In 2019, single low dose primaquine in 
addition to artemisinin-based combination treatment 
was introduced in South Africa to reduce onward 
transmission.23 Intravenous artesunate is used to treat 
severe malaria. Health workers classify cases as imported 
if the onset of symptoms occurred 7–30 days after travel 
to a malaria endemic area outside the country.24 All deaths 
of people diagnosed with malaria are investigated by a 
clinician affiliated with the provincial malaria control 
programmes.
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Research in context
Evidence before this study
We searched PubMed on June 30, 2020, using the terms 
“vector control” AND “malaria” AND “reactive” AND “target*”, 
with no restriction on language or dates. The search identified 
three studies detailing work done in Zambia evaluating the 
use of reactive case detection, in addition to standard vector 
control. The search identified one study that evaluated 
reactive indoor residual spraying (IRS) using pirimiphosmethyl 
as an adjunct to pre-season blanket IRS in Namibia. This large 
cluster-randomised controlled trial found that reactive vector 
control (involving IRS of at least seven households within 
500 m of an index household) resulted in lower malaria case 
incidence (adjusted rate ratio 0·48, 95% CI 0·16–0·80; 
p=0·002) compared with clusters that only received 
pre-season spraying. This study did not publish 
cost-effectiveness estimates, although it was mentioned that 
there are plans to publish this information. Empirical evidence 
on the effectiveness of targeted reactive vector control is 
therefore scarce and no published evidence is available 
regarding the cost-effectiveness of such strategies. There have 
been no previous studies that investigated whether routine 
blanket vector control can be safely replaced with reactive 
targeted vector control.
Added value of this study
We did a cluster-randomised trial over two malaria seasons 
(2015–17) in a very-low-transmission setting in northeastern 
South Africa to compare annual mass IRS campaigns with a 
reactive, targeted IRS strategy. We showed that reactive, targeted 
spraying was non-inferior to routine mass spraying on the basis 
of our prespecified margin of fewer than 1 additional case per 
1000 person-years. We collected cost data during the trial and 
modelled the cost-effectiveness of switching from an untargeted 
to a targeted strategy. At the incidence observed in the trial 
(0·9 local cases per 1000 person-years), we found that a targeted 
strategy would have a 94–98% probability of being cost-
effective, and would be cost-effective up to an incidence of 
2·0–2·7 cases per 1000 person-years.
Implications of all the available evidence
Together with previous evidence, this study suggests that 
targeted IRS could be cautiously implemented as an alternative 
to annual IRS campaigns in areas with very low malaria 
transmission and strong surveillance systems. Doing so would 
enable scarce resources available for malaria control to be more 
effectively used for other life-saving activities, such as enhanced 
case detection or increased disease surveillance.
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This study took place between Aug 1, 2015, and 
July 31, 2017, in the predominantly rural subdistricts 
of Bushbuckridge in Mpumalanga province and 
Ba-Phalaborwa in Limpopo province (figure 1).25 In the 
study area, malaria incidence ranges between fewer 
than 1 case per 1000 person-years and 5 cases per 
1000 person-years, and malaria is mostly locally acquired 
and seasonal between October and May.20,25,26 Neither 
pyrethroid nor DDT resistance have been reported in the 
trial provinces.27,28
Census wards were mapped and formed into clusters 
comprising populations of about 5000–10 000 people. To 
be eligible for inclusion in the trial, clusters required a 
history of local cases in at least one year in the 5 years 
before the trial (Aug 1, 2010–July 31, 2015). Wherever 
possible, clusters were separated by natural boundaries 
or uninhabited space. Around 400 000 people resided 
within the trial clusters, the majority in Mpumalanga 
province (72%).
The trial’s objective was to determine whether targeted 
IRS is non-inferior to the standard strategy, standard 
IRS, within a specified margin of non-inferiority, using 
passively reported malaria incidence as the primary 
outcome. A non-inferiority margin of 1 case per 
1000 person-years was chosen; a greater difference in 
incidence between study groups would be important 
because South Africa’s malaria elimination plan aimed 
to reduce incidence in all areas to below this threshold.
Figure 1: Study location
(A) Location of trial provinces. (B) Location of clusters within trial provinces. (C) Allocation of clusters to study groups within Mpumalanga. (D) Allocation of clusters 
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Ethics approvals were provided by institutional review 
boards at the London School of Hygiene & Tropical 
Medicine (7396-1), University of Witwatersrand 
(M140762), and Mpumalanga and Limpopo Provincial 
Departments of Health. An amendment detailing minor 
changes to the trial protocol was submitted on Oct 7, 2015 
(appendix p 16), and ethics approval received on 
Dec 10, 2015. Community consent was sought through 
public meetings and discussions with ward councillors. 
During case investigation visits, written informed 
consent was obtained from householders. Independent 
trial steering and data safety monitoring committees 
oversaw the trial.
Randomisation and masking 
Clusters were randomly assigned (1:1) to receive either 
standard IRS or targeted IRS using restricted random-
isation to balance study groups on pre-existing 
characteristics that might have been associated with the 
trial outcome. Restriction criteria were mean malaria 
incidence between Aug 1, 2010, and July 31, 2015 (obtained 
from the provincial reporting system), province, population 
size, proportion of households sprayed with IRS in 2014, 
population density, and total length of streams and rivers. 
The allocation of clusters to study groups was finalised at a 
randomisation ceremony attended by ward councillors. 
Blinding of communities or research personnel to study 
groups was not possible; however, data analysis was 
masked by labelling the groups as A and B.
Procedures
The reference group, standard IRS, comprised the 
standard practice of annual mass spray campaigns by the 
provincial malaria control programmes, using either 
DDT or the pyrethroids deltamethrin (Bayer; Isando, 
South Africa) or α-cypermethrin (Efekto; Isando, 
South Africa). Spray training commenced in August, 
before the start of the malaria season, and spraying 
continued until December in both years. Following 
standard procedures, programme managers prioritised 
at-risk areas, such as those close to rivers and streams, on 
the basis of the number of malaria cases in the previous 
season, malaria control programme expert opinion, 
and available budget. Around a third of households in 
standard IRS clusters were sprayed annually through this 
informal targeting process. Spray operations were led by 
environmental health practitioners, who trained teams of 
seasonal contract sprayers over a 2-week period.
Confirmed malaria cases at health facilities are reported 
to the provincial malaria control programme within 24 h, 
triggering a case investigation.29 During the study, the 
provincial malaria control programme contacted the 
study coordinator to determine whether cases were in 
the study area and, if so, in which study group. In 
standard IRS clusters, case investigation teams were 
employed by the provincial malaria control programme. 
During an investigation, they administered a short 
questionnaire on recent travel history to determine 
whether the case was imported or locally acquired, 
following standard guidelines.24 If confirmed as locally 
acquired, the index case house was sprayed only if it had 
not already been sprayed during the annual spray round. 
Any household member reporting fever was tested using 
a malaria rapid diagnostic test and referred for treatment 
to the nearest health facility if positive.
In the intervention group, targeted IRS, no annual 
mass spray campaigns were done. Case investigations 
were triggered in the same way as in standard IRS 
clusters; however, case investigation teams were 
employed by the trial. In addition to case investigation 
activities, the teams sprayed the interiors of locally 
acquired index case houses and up to eight neighbouring 
houses (around 50 structures) within 200 m with 
deltamethrin, regardless of wall type, subject to consent 
of householders. DDT was considered unsuitable for 
targeted IRS, because most houses in the study area have 
painted surfaces. Malaria testing and referral was 
identical to standard IRS clusters. Further details of the 
interventions are provided in the appendix (pp 2–5).
To verify the quality of spray application, susceptible 
adult A arabiensis laboratory colony mosquitoes main-
tained at the Limpopo Malaria Control Programme 
insectary in Tzaneen were used for standard cone bioassay 
testing within 2–4 weeks of spraying in a random sample 
of households in the targeted IRS group.30,31 Standard IRS 
was intended to represent standard practice, so no 
additional quality checks were done.
Case investigation data were collected on handheld 
tablet computers using an application (Mobenzi 
Researcher) developed for the trial, uploaded in real time 
using cellular network to a cloud-based server, and 
validated and analysed using Microsoft Excel 2016 and 
Stata version 15.
Outcomes 
The primary outcome, malaria incidence, was recorded 
through passive case detection at all health facilities 
within the subdistrict, as reported to the malaria control 
programme. Clinical malaria was diagnosed if the patient 
presented with a fever (axillary temperature ≥37·5°C) or 
history of fever (in the past 48 h), in the presence of 
parasitaemia confirmed by rapid diagnostic test or 
microscopy. Cases classified as imported were excluded 
from analysis. The trial data safety monitoring committee 
assessed reports of delays between diagnosis of cases and 
spraying in the targeted IRS group, and numbers of 
malaria cases and deaths between study groups to detect 
any unexpected increase in the targeted IRS group. 
Reports of malaria-associated deaths were submitted by 
the principal investigator to the data safety monitoring 
committee immediately after the provincial health 
department completed its investigation.
An endline cross-sectional survey was done from 
June 12 to Aug 16, 2017, to assess additional secondary 
See Online for appendix
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outcomes, including household compliance, population 
attitudes to IRS, and serological markers. The proportion 
of structures targeted for IRS that were not sprayed 
and the reasons why structures were not sprayed, both 
secondary outcomes of the trial, were not consis tently 
collected and hence not reported. Testing for insecticide 
resistance could not be done, because collection of suf-
ficient mosquitoes for standard tests proved impossible.
Statistical analysis 
For sample size calculations, mean incidence of locally 
acquired malaria in the reference group was assumed to 
be 2·2 per 1000 person-years on the basis of historical data. 
Assuming a coefficient of variation between clusters 
of 0·5, the trial required 31 clusters per group (62 in total) 
of 6000 people each over 2 years (12 000 person-years 
per cluster) for 80% power at two-sided 5% (2·5% one-sided) 
significance to show non-inferiority within a margin of 
1 case per 1000 person-years.32
The primary outcome, malaria incidence per cluster, 
was calculated from local cases recorded at health 
facilities and the cluster population recorded in the 
2011 national census, projected forward. Cases were 
allocated to clusters on the basis of the place of residence 
provided by patients at the time of diagnosis and 
confirmed during case investigations. Incidence by group 
was calculated as the mean of the cluster incidences 
allowing for the clustered design. To assess non-
inferiority, the incidence rate difference between study 
groups was estimated using linear regression on the 
cluster incidences with and without adjustment for 
province. Two-sided 95% CIs, corresponding to one-sided 
97·5% intervals, and two-sided 90% CIs, corresponding 
to one-sided 95% intervals, were calculated as standard 
for non-inferiority tests. The upper limit of the CI of the 
difference in rates between study groups was compared 
with the prespecified margin of non-inferiority. p values 
indicate the probability of obtaining the given result by 
chance if the true rate difference is greater than the 
specified non-inferiority margin—ie, more than 1 case 
per 1000 person-years. Poisson regression adjusting for 
province was used to calculate rate ratios for cost-
effectiveness analyses.33
Cost-effectiveness analysis
Resource use and cost of each resource (ie, unit cost) 
were collected to model the real-world cost for the 
provincial malaria control programme to implement 
either standard IRS or targeted IRS as standard practice. 
Costs were estimated for each strategy using a 
combination of top-down and bottom-up costing.34 The 
focus was on economic costs, which reflect the full value 
of all resources used; however, almost all economic costs 
were also financial costs, meaning they involved 
monetary payment. A health services perspective was 
adopted, which included the costs of spraying, case 
investigations, training, supervision, diagnosis, and 
treatment; costs borne by households were excluded due 
to lack of data. Set-up costs for targeted IRS and recurrent 
costs for standard IRS and targeted IRS were estimated. 
Costs for the provincial malaria control programme to 
set up targeted IRS, including training, were annualised 
assuming a useful life of 3 years. Costs were estimated 
for Mpumalanga province only (where 49 of the 
62 clusters were located), because detailed accounts from 
the Limpopo Malaria Control Programme were 
unavailable. Research costs were excluded.
Where implementation costs incurred during the 
trial were expected to differ from real-world imple-
mentation outside a trial, cost estimates were adjusted 
to best approximate real-world implementation. All 
resources were costed using unit costs from the 
Mpumalanga Malaria Control Programme, even where 
the trial obtained them (for targeted IRS) at a different 
unit cost. It was assumed that implementation of targeted 
IRS would not change malaria control programme 
management and overheads, and that environmental 
health practitioners leading the annual mass spray 
campaigns would remain employed under targeted IRS.
The cost per case diagnosed and treated was assumed 
to be the same under either strategy and estimated from 
available secondary data (appendix pp 6–8).35–37 Costs 
were estimated for a standardised population of 100 000 
in constant 2017 US$.38 Details of costing methods are 
provided in the appendix (pp 9–13).
The incremental cost savings per disability-adjusted 
life-year (DALY) incurred by targeted IRS compared with 
standard IRS were calculated to determine whether 
switching to targeted IRS would be cost-effective. This 
formulation differs from (but is equivalent to) the typical 
presentation of incremental cost per DALY averted, 
because targeted IRS is designed to be less costly but 
potentially (slightly) less effective than its comparator. 
Incremental cost-effectiveness ratios (ICERs) were 
compared with the lowest ($2637, 43% of gross domestic 
product [GDP] per capita) and highest ($3557, 58% of 
GDP per capita) of four cost-effectiveness thresholds,39 
which reflect the benefits forgone in withdrawing 
Standard IRS group Targeted IRS group
Number of clusters 31 31
Mpumalanga 24 25
Limpopo 7 6
Mean cluster population (SD) 6102 (3254) 6588 (2225)
Mean number of households per cluster (SD) 1534 (802) 1619 (545)
Mean population density per cluster (SD) 1095 (447) 1091 (510)
Mean annual local malaria case incidence per 
1000 population for 2010–15 (SD)
1·05 (0·89) 0·88 (0·89)
Mean percentage of households sprayed by IRS in 
the previous year (SD)
41·4% (29·3) 38·7% (23·2)
IRS=indoor residual spraying.
Table 1: Baseline characteristics
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resources from an existing intervention in South Africa. 
Cost-effectiveness results were estimated overall (ie, for 
both years combined) and by year.
A decision tree was used to model costs and health 
outcomes over a lifetime horizon (appendix p 14). DALYs 
were modelled as the sum of years of life lost and years 
of life lived with disability using a discount rate of 
3% and no age weighting (appendix p 15).40
The impact of uncertainty in individual input 
parameters on cost-effectiveness was explored through 
deterministic sensitivity analysis by varying parameters 
individually across plausible value ranges. Probabilistic 
sensitivity analysis was done to explore the combined 
impact of parameter uncertainty. Proportions were 
assumed to follow beta distributions; non-negative 
parameters, such as costs, were assumed to be gamma 
distributed. By use of Monte Carlo simulation, 
10 000 samples were drawn from the parameter 
distributions and used to calculate incremental costs 
and effects, which were plotted on the cost-effectiveness 
plane alongside cost-effectiveness thresholds. Mean 
ICERs were calculated as the mean incremental cost 
across iterations divided by the mean incremental 
DALYs across iterations. 95% credible intervals were 
calculated as percentiles of the ICER distribution. 
Using cost-effectiveness acceptability curves,41 the 
probability that switching from standard to targeted 
IRS would be cost-effective at different thresholds was 
calculated.
Malaria incidence at which the more cost-effective 
strategy would change was calculated in a threshold 
analysis. For targeted IRS, it was assumed that the cost of 
insecticide, as well as diagnostic and treatment costs, 
would increase in proportion to the number of cases, but 
that other resources associated with case investigations 
(case investigators, equipment, and transport costs) would 
remain fixed. For standard IRS, only diagnostic and 
treatment costs were assumed to vary with the number of 
cases; all other resources would remain fixed. Incidence 
was varied until the ICER (for the 2 years combined) 
equalled each of the cost-effectiveness thresholds. Details 
of model parameters are provided in the appendix (pp 6–8).
This study is registered with ClinicalTrials.gov, 
NCT02556242.





Number of clusters 31 31 62 ·· ··
Study population 189 150 204 237 393 387 ·· ··
Year 1
Number of local malaria cases 7 13 20 ·· ··
Number of deaths 1 0 1 ·· ··
Crude incidence per 1000 person-years 0·04 0·06 0·05 ·· ··
Total economic cost per 
100 000 population, constant 2017 US$
$189 118 $85 432 ·· ·· –$103 685 (–55%)
Economic cost per structure sprayed, 
constant 2017 US$
$2·78 $737·86 ·· ·· $735·07 (26 409%)
Year 2
Number of local malaria cases 304 381 685 ·· ··
Number of deaths 11 9 20 ·· ··
Crude incidence per 1000 person-years 1·64 1·94 1·74 ·· ··
Total economic cost per 
100 000 population, constant 2017 US$
$178 861 $90 733 ·· ·· –$88 127 (–49%)
Economic cost per structure sprayed, 
constant 2017 US$
$3·75 $26·20 ·· ·· $22·45 (598%)
Total
Number of local malaria cases 311 394 705 ·· ··
Number of deaths 12 9 21 ·· ··
Crude incidence per 1000 person-years 0·82 0·96 0·90 ·· ··






·· 0·10  
(–0·38 to 0·59)†
··
Total economic cost per 
100 000 population, constant 2017 US$
$184 319 $88 258 ·· ·· –$96 061 (–52%)
Economic cost per structure sprayed, 
constant 2017 US$
$3·19 $49·23 ·· ·· $46·05 (1444%)
IRS=indoor residual spraying. *Mean of cluster incidences. †Non-inferiority p value <0·0001.
Table 2: Local malaria cases, crude incidence, and cost, by year and study group
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Role of the funding source 
The funder of the study had no role in study design, data 
col lection, data analysis, data interpretation, or writing of 
the report.
Results 
The study profile is provided in the appendix (p 17). 
Characteristics at baseline are summarised in table 1. 
During the 2-year trial period, 1030 malaria cases were 
recorded, of which 705 (68%) were classified as locally 
acquired, corresponding to a crude incidence of 0·90 local 
cases per 1000 person-years (table 2). In Limpopo, 
incidence was 1·88 cases per 1000 person-years and in 
Mpumalanga 0·65 cases per 1000 person-years. Annual 
incidence was 0·05 per 1000 person-years (n=20) in year 1 
and 1·74 per 1000 person-years (n=685) in year 2. 
Incidence by cluster varied from zero cases (seven clusters, 
all in Mpumalanga: three in the standard IRS group and 
four in the targeted IRS group) to more than 3 cases 
per 1000 person-years (four clusters, of which three were 
in Limpopo: two in the standard IRS group and two in the 
targeted IRS group). Case incidence varied substantially 
over time, peaking in May, 2017, when 54% (n=383) of all 
locally acquired cases occurred (appendix p 18). Median 
age of individuals with locally acquired malaria was 
27 years (IQR 10–37; range 0–91), and 373 (53%) of 
705 cases occurred in men.
There were 21 deaths (12 in the standard IRS group and 
nine in the targeted IRS group) associated with locally 
acquired malaria during the study period, corresponding 
to a case fatality rate of 3·0% (table 2). The median age at 
death was 40 years (IQR 34–53; range 22–66). The most 
common factors contributing to death were late 
presentation (n=8) and patients not being tested for 
malaria at first presentation (n=5). No other serious 
adverse events were reported.
In Mpumalanga, 128 519 structures (broadly defined as 
individual rooms within a house or outbuilding) were 
sprayed in standard IRS clusters in the first year and 
90 196 in the second; in targeted IRS clusters, 132 and 
6163 structures were sprayed in the same periods. In 
Limpopo, 150 structures were sprayed in targeted IRS 
clusters in the first year and 1622 in the second; data on 
the number of structures sprayed in standard IRS 
clusters were not available for Limpopo (appendix p 17). 
In the targeted IRS group, teams sprayed on average 
3·7 neighbouring houses per investigation, despite 
repeat visits. Case investigation teams reported that, due 
to scattered settlement patterns, index case houses often 
had fewer than eight houses within 200 m. Cone bioassay 
testing done on 14 sprayed structures in the targeted IRS 
group reported an overall 24-h mosquito mortality 
of 99·5% (n=420), providing assurance of satisfactory 
insecticide application. Results of the endline survey are 
reported in the appendix (p 19).
Malaria case incidence was 0·95 per 1000 person-years 
(95% CI 0·58 to 1·32; n=311) in the standard IRS group 
and 1·05 per 1000 person-years (95% CI 0·72 to 1·38; 
n=394) in the targeted IRS group (table 2); the rate 
difference was 0·10 (95% CI –0·38 to 0·59), equivalent to 
one extra case for every 10 000 people in the targeted 
IRS group (figure 2). There was strong evidence of 
Figure 2: Rate difference between targeted IRS and standard IRS for 2-year study period
This figure shows the rate difference between annual cluster incidence, crude and adjusted for province, with 
large caps representing 95% CIs and smaller caps representing 90% CIs. The red dotted vertical line represents 
the non-inferiority margin (1 case per 1000 person-years increase in incidence). Non-inferiority p value is the 
probability of obtaining the rate difference by chance if the actual difference is more than 1. Margin of 
non-inferiority is breached if CIs encompass 1. IRS=indoor residual spraying.




Rate difference 0·10, 95% CI –0·38 to 0·59, 
90% CI –0·30 to 0·51; p<0·0001
Rate difference 0·14, 95% CI –0·27 to 0·55, 
90% CI –0·20 to 0·48; p<0·0001
Figure 3: Cost-effectiveness plane
Economic cost savings (from a health service perspective) and DALYs incurred 
by switching from standard IRS to targeted IRS are shown for the 2-year trial 
period (A) and individual study years (B). Costs and DALYs shown in the figure 
are incremental with respect to standard IRS (which is shown at [0,0]) in each 
study year. The large dots show the mean incremental cost and mean 
incremental DALYs across the 10 000 model simulations. Individual model 
simulations are shown as smaller dots, for each year. DALY=disability-adjusted 





























Cost-effectiveness threshold, South Africa (low) 
(US$2637 per DALY averted)
Cost-effectiveness threshold, South Africa (high) 

















































www.thelancet.com   Vol 397   February 27, 2021 823
non-inferiority of targeted IRS compared with standard 
IRS within the predefined margin of 1 case per 1000 person-
years at the 2·5% one-sided significance level (p<0·0001). 
Adjusted for province, the rate difference was 0·14 
(95% CI –0·27 to 0·55; figure 2). Further sensitivity 
analysis is reported in the appendix (p 20). In year 1, 
there was strong evidence that targeted IRS was non-
inferior to standard IRS (adjusted rate difference 0·04, 
95% CI –0·07 to 0·16; p<0·0001). For year 2, the 95% CIs 
crossed the non-inferiority margin for both the crude and 
adjusted rate differences, but the 90% CI (equivalent 
to 5% one-sided significance level) for both estimates 
remained below the non-inferiority threshold (adjusted 
rate difference 0·24, 95% CI –0·54 to 1·03, 90% CI 
–0·41 to 0·90; p=0·058; appendix p 21).
The average annual economic cost was $88 258 per 
100 000 population for targeted IRS, 52% less than 
standard IRS ($184 319; table 2). Targeted IRS cost less, 
because it involved spraying fewer structures (around 3% 
of the structures sprayed in standard IRS), it did not use 
contract sprayers, and it used substantially less 
insecticide, transport, and equipment. Except for contract 
sprayers, personnel costs were similar across the two 
groups. Malaria treatment costs comprised a very small 
proportion of total costs under standard (0·9%) and 
targeted (2·3%) IRS. Further results by cost component 
are reported in the appendix (p 22).
Across the 2-year trial, targeted IRS saved $7845 
(95% CI 2902–64 907) for each additional DALY incurred 
relative to standard IRS (figure 3). In year 1, when 
incidence was lower, targeted IRS saved $35 149 for each 
additional DALY incurred; the lower bound of the 95% CI 
was $6481 and at the higher bound targeted IRS was 
dominant—ie, less expensive and more effective than 
standard IRS. In year 2, when incidence was higher, 
targeted IRS saved $3869 (95% CI $1371–$50 689) 
per DALY incurred. At both cost-effectiveness thresholds 
($2637 and $3557), targeted IRS would be considered 
cost-effective across the trial period and in each of the 
2 years (figure 3)—ie, the cost savings from switching 
from standard to targeted IRS would be expected to 
generate greater net health benefits if invested elsewhere 
in the health system. At the incidence observed in the 
trial, targeted IRS would have a 94–98% probability of 
being the cost-effective choice at either cost-effectiveness 
threshold (figure 3; appendix p 23).
The finding that targeted IRS was cost-effective across 
the 2-year trial period is robust to plausible variation in all 
Figure 4: Deterministic sensitivity of ICERs to plausible variation in individual model parameters
Where targeted IRS is the dominant strategy (ie, less costly and more effective than standard IRS), this has been stated in the cell. DALY=disability-adjusted life-year. ICER=incremental cost-
effectiveness ratio. IRS=indoor residual spraying. NA=not applicable. *ICER estimates are based on best estimates for each parameter; therefore, they slightly differ from the ICER estimates presented in 
the main text, which are calculated as the mean incremental cost savings divided by the mean incremental DALYs from 10 000 model simulations. †Adjusted for province. ‡Contract sprayer-days is the 
number of contract sprayers employed each year multiplied by the number of days in the annual mass spraying season.
All parameters*
Discount rate
Incidence rate with standard IRS, local cases
per 1000 person-years (95% CI)
Rate ratio†
Case fatality rate
Years of life lost per death (discounted)
Cost per kg of insecticide (DDT and
deltamethrin) as proportion of base case cost
Contract sprayer-days‡ per spray season
Environmental health practitioners per 
100 000 population retained in targeted IRS
Case investigators per 100 000 population
required in targeted IRS
Best estimate for each parameter
3·0% (1·0–10·0)
Year 1: 0·06 (0·00–0·13)
Year 2: 1·83 (1·10–2·56)
Both: 0·95 (0·58–1·32)
Year 1: 1·81 (0·72–4·53)





Year 1: 13 750 (10 313–17 188)
Year 2: 14 300 (10 725–17 875)




Wilkinson et al (2016; standard assumptions)40
Trial estimates based on passive surveillance 
(95% CI)
Trial estimates based on passive surveillance 
(95% CI)
Trial estimates based on passive surveillance 
(South African case fatality rate for malaria [2016],
assumption)1
Trial data on sex and age at death; Global Health 
Observatory life tables, South African life 
expectancy (Japanese life expectancy)42
Mpumalanga Malaria Control Programme financial 
accounts (–20%, +100%)
Mpumalanga Malaria Control Programme financial 
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Mpumalanga Malaria Control Programme 
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Best estimate (range) Source for best estimate (source for range) ICER (economic cost savings per DALY incurred in switching 
from standard to targeted IRS), constant 2017 US$
Year 1 Year 2 Total (both years)
Low High Low LowHigh High
Targeted IRS is cost-effective at both cost-effectiveness thresholds ($2637 and $3557 per DALY averted)
Targeted IRS would only be cost-effective at the lower (more conservative) cost-effectiveness threshold ($2637 per DALY averted)
Targeted IRS would not be cost-effective at either cost-effectiveness threshold ($2637 or $3557 per DALY averted)
Articles
824 www.thelancet.com   Vol 397   February 27, 2021
individual parameters evaluated (figure 4) and to re-analysis 
on the basis of Mpumalanga-specific incidence and rate 
ratios (appendix p 25). Year 1 results are similarly robust. If 
implemented in year 2 only, when incidence was higher, 
targeted IRS would not be cost-effective with respect to 
either of the cost-effectiveness thresholds if the rate ratio 
were at the upper bound of the 95% CI; targeted IRS would 
be cost-effective at the lower but not the higher threshold 
for plausible variation in six of the eight other parameters 
explored (figure 4). If all parameters except incidence 
remained constant, we estimated that targeted IRS would 
remain the preferred strategy up to an incidence of 
2·0–2·7 cases per 1000 person-years, using the higher and 
the lower cost-effectiveness thresholds.
Discussion 
This study has shown that reactive, targeted IRS in 
response to index cases was non-inferior to mass annual 
IRS campaigns, which prioritise areas selected on the 
basis of historical information and expert opinion, within 
a margin of 1 case per 1000 person-years in this low-
transmission setting in South Africa. In this context, 
changing from standard to targeted IRS would be a more 
efficient use of scarce malaria control programme 
resources, while providing non-inferior malaria pro-
tection. By adopting targeted IRS, the malaria control 
programme would make substantial savings, which could 
be redirected to other, potentially more efficient and life-
saving malaria interventions, such as improved awareness 
of malaria risk among affected communities and health-
care providers, enhanced case management, surveillance, 
and border screening. If targeted IRS were standard 
practice in this setting, adoption of standard IRS (at an 
ICER of $7845 per DALY averted) would not be considered 
cost-effective. However, replacing the existing standard 
IRS intervention that has been in place for many years 
would be politically and socially sensitive43 and would 
require caution and vigilance to avoid resurgence in cases.
These findings were generally robust to plausible 
changes in key parameters and are conservative in 
several ways. Cost savings would have been greater if we 
had included the substantial increases in insecticide 
costs that are expected when insecticide resistance 
necessitates a switch to more expensive next generation 
insecticides.5,44 Although South Africa’s overall malaria 
case fatality rate was 0·79% in the first study year and 
1·06% in the second,1 our cost-effectiveness estimates 
were based on the observed study case fatality rate of 
3·0%. Although mortality was similar in the two study 
groups, at lower overall case fatality rates, targeted IRS 
would be more cost-effective because any additional 
cases (relative to standard IRS) would result in fewer 
deaths and DALYs. Targeted IRS was much more 
cost-effective in year 1 than year 2, due to substantial 
between-year heterogeneity in incidence; however, 
targeted IRS remained the more cost-effective strategy 
(61–78% probability) in year 2 (appendix p 23).
In South Africa, malaria incidence often varies 
substantially between years.1,22 Incidence was markedly 
higher during the second year of this study than the first.1 
In standard IRS clusters, fewer structures were sprayed 
in year 2 because the informal targeting is based partly 
on the (very low) malaria incidence in the preceding 
season. In targeted IRS clusters, more structures were 
sprayed in year 2 in accordance with the protocol. The 
increased incidence resulted in some delays to the 
reactive spraying, which might have caused onward 
transmission and an increase in case numbers. In year 2, 
targeted IRS remained non-inferior to standard IRS at 
the one-sided 5% significance level, but not at the 
2·5% significance level. The finding of more marginal 
non-inferiority at higher incidence should be interpreted 
with caution, however, because the trial was not powered 
to demonstrate non-inferiority in individual study years.
Our study has several limitations. First, incidence was 
measured using passive case detection, so any 
asymptomatic infections that could lead to onward malaria 
transmission would remain undetected. In South Africa, 
however, the vast majority of cases are symptomatic 
because the population does not have partial immunity, 
due to low exposure to malaria parasites. Additionally, self-
medication is unlikely because the informal sector does 
not sell antimalarials. We therefore consider passive case 
detection robust in this setting. Second, possible 
misclassification of local cases as imported might have 
reduced the impact of the targeted IRS strategy because 
reactive spraying was only done in response to locally 
acquired cases. Third, in the targeted IRS group, fewer 
than half of the intended eight neighbouring houses were 
sprayed on average. Although the intervention would 
be more expensive at higher coverage, it might also be 
more effective. Fourth, costs were only estimated for 
Mpumalanga province, as such information was not 
available from Limpopo; however, results are robust to 
wide variation in unit costs and resource use (figure 4). 
Fifth, we did not quantify the inconvenience or potential 
secondary benefits (such as insect control) of receiving 
IRS or the costs to households of experiencing and 
seeking treatment for malaria; however, we expect these 
factors to have a relatively small incremental impact. 
Finally, we assumed that real-world implementation of 
targeted IRS by the provincial malaria control programme 
would achieve similar effectiveness as the trial without 
additional management and supervision. We consider 
this assumption reasonable because malaria control 
programme managers (who would deliver targeted IRS in 
a future implementation) receive similar remuneration to 
the trial managers who delivered targeted IRS in the study, 
and because we conservatively assumed that staff 
managing the spray programme would be retained 
(appendix pp 9–13).
This trial is the first to directly compare reactive IRS 
with annual, mass IRS campaigns. Previous studies 
have evaluated the effect of adding reactive targeted 
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interventions, including IRS and drug administration, to 
routine population-wide measures, to further reduce or 
eliminate malaria.13,14,45–47 A trial in Namibia showed 
effective reduction of malaria incidence through reactive 
focal mass drug administration and reactive focal IRS, 
alone and in combination, when added to standard IRS.14 
Our trial is unique in using a non-inferiority design to 
assess whether replacing annual IRS campaigns with 
reactive IRS targeting at-risk neighbourhoods would be 
safe and prevent malaria from surging out of control. As 
governments seek more sustainable strategies to enable 
the best use of scarce resources, non-inferiority trials 
could become more commonplace.
We expect our findings to be generalisable to very-low-
transmission settings with well functioning surveillance 
systems. The reference, standard IRS, already uses 
informal targeting, prioritising areas on the basis of the 
resources available, local information, and malaria 
incidence in the previous year. Because many countries 
have adopted similar targeting strategies,48,49 our findings 
regarding a cost-effective, data-driven, alternative strategy 
are expected to be widely relevant. The reactive targeted 
strategy we evaluated relies on well functioning 
surveillance systems; such systems are considered 
essential by WHO for countries pursuing malaria 
elimination.50,51 Our results showed that targeted IRS 
would cease to be cost-effective in South Africa above an 
incidence of 2·0–2·7 per 1000 person-years, depending on 
the cost-effectiveness threshold used. We would therefore 
only recommend this strategy when transmission is 
proven to be very low through reliable case reporting.
This study highlighted weaknesses in malaria control 
that would benefit from investment, which could be 
achieved with the savings obtained from targeted IRS. The 
observed case fatality rate was high and indicated the need 
for appropriate interventions. Despite good knowledge 
about malaria reported in a household survey,52 some of 
the deaths during the study period were attributed to late 
presentation to a health facility, which could reflect low 
care seeking in populations in which malaria is rare.53 
Lack of malaria testing at first presentation was also stated 
on some death reports, and might be associated with 
stockouts of rapid diagnostic tests at health facilities that, 
although infrequent, occurred during the trial.54 Malaria 
deaths have declined in number in South Africa since 2017 
in response to corrective action that has already been 
implemented at health facilities.55 Reallocation of resources 
to comprehensive awareness campaigns encouraging 
prompt facility visits in response to symptoms and routine 
testing for malaria even when cases are rare could reduce 
or eliminate malaria mortality. Enhanced resilience 
against malaria commodity stockouts would further 
reduce the potential for malaria deaths. Additional 
investment could reduce the time interval between case 
diagnosis and case investigation. To minimise onward 
transmission, case investigations need to occur promptly, 
ideally within 48 h of case detection. In this trial, case 
investigations were frequently delayed when cases were 
more numerous, consistent with previous findings in 
South Africa.20 Case reporting using mobile phones56,42 has 
since been implemented and has helped improve 
response times. Sufficient standby capacity of case 
investigation teams in a targeted IRS strategy will be 
essential to ensure that health services are prepared for 
unexpected surges in cases.
The commitment by heads of states in the Southern 
African Development Community to eliminate malaria in 
the region by 203057 is commendable and ambitious. 
Fulfilling this goal will require identification of the most 
cost-effective ways to allocate scarce resources in 
changing epidemiological contexts. The withdrawal of 
mass prevention efforts in an uncoordinated manner 
motivated solely by cost considerations would be 
irresponsible and risk a rebound in malaria. The strategy 
presented here, reactive targeting of IRS on the basis of 
evidence of recent transmission, was shown to be safe 
and highly cost-effective in a pre-elimination setting and 
could free up vital resources for other, life-saving malaria 
services. Its implementation should be cautiously 
considered in settings where malaria transmission is 
already very low, case surveillance is robust, and health 
systems are able to respond nimbly to resurgent 
outbreaks.
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